The Cytoplasmic Domain of Rhesus Cytomegalovirus Rh178 Interrupts Translation of Major Histocompatibility Class I Leader Peptide-containing Proteins Prior to Translocation
Overview
Affiliations
Cytomegalovirus (CMV) efficiently evades many host immune defenses and encodes a number of proteins that prevent antigen presentation by major histocompatibility complex class I (MHC-I) molecules in order to evade recognition and killing of infected cells by cytotoxic CD8(+) T cells. We recently showed that rhesus CMV-specific Rh178 intercepts MHC-I protein translation before interference of MHC-I maturation by homologues of the human CMV US6 family. Here, we demonstrate that Rh178 localizes to the membrane of the endoplasmic reticulum, displaying a short luminal and large cytosolic domain, and that the membrane-proximal cytosolic portion is essential for inhibition of MHC-I expression. We further observed that Rh178 does not require synthesis of full-length MHC-I heavy chains but is capable of inhibiting the translation of short, unstable amino-terminal fragments of MHC-I. Moreover, the transfer of amino-terminal fragments containing the MHC-I signal peptide renders recipient proteins susceptible to targeting by Rh178. The cytosolic orientation of Rh178 and its ability to target protein fragments carrying the MHC-I signal peptide are consistent with Rh178 intercepting partially translated MHC-I heavy chains after signal recognition particle-dependent transfer to the endoplasmic reticulum membrane. However, interference with MHC-I translation by Rh178 seems to occur prior to SEC61-dependent protein translocation, since inhibition of MHC-I translocation by eeyarestatin 1 resulted in a full-length degradation intermediate that can be stabilized by proteasome inhibitors. These data are consistent with Rh178 blocking protein translation of MHC-I heavy chains at a step prior to the start of translocation, thereby downregulating MHC-I at a very early stage of translation.
Human cytomegalovirus UL18 prevents priming of MHC-E- and MHC-II-restricted CD8 T cells.
Malouli D, Taher H, Mansouri M, Iyer R, Reed J, Papen C Sci Immunol. 2024; 9(100):eadp5216.
PMID: 39392895 PMC: 11797217. DOI: 10.1126/sciimmunol.adp5216.
Brackenridge S, John N, He W, Fruh K, Borrow P, McMichael A J Virol. 2024; 98(9):e0120624.
PMID: 39207137 PMC: 11406984. DOI: 10.1128/jvi.01206-24.
Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacy.
Verweij M, Hansen S, Iyer R, John N, Malouli D, Morrow D Science. 2021; 372(6541).
PMID: 33766941 PMC: 8354429. DOI: 10.1126/science.abe9233.
Petti L, Marlatt S, Luo Y, Scheideman E, Shelar A, DiMaio D J Biol Chem. 2018; 293(23):8787-8801.
PMID: 29678881 PMC: 5995508. DOI: 10.1074/jbc.RA117.001067.
Broadly targeted CD8⁺ T cell responses restricted by major histocompatibility complex E.
Hansen S, Wu H, Burwitz B, Hughes C, Hammond K, Ventura A Science. 2016; 351(6274):714-20.
PMID: 26797147 PMC: 4769032. DOI: 10.1126/science.aac9475.